Indian contract services provider Shasun Chemicals & Drugs Ltd has forayed the fast-emerging biogenerics segment by launching its generic version of the recombinant streptokinase in the Indian market.
The Chennai-based Shasun is one of the prominent custom research and manufacturing services (CRAMS) player and a leading supplier of several active pharmaceutical ingredients including ibuprofen etc.
Shasun developed the biotherapeutic recombinant streptokinase under public-private-partnership. The technology for streptokinase was developed by the Chandigarh-based Institute of Microbial Technology (IMTech), a constituent laboratory of the Council of Scientific and Industrial Research (CSIR).
According to some estimates, the streptokinase market in the country is over $17 million growing in double digits.
Apart from Shasun, Shantha Biotechnics (Shankinase), Bharat Biotech India Ltd (Indikinase), Virchow Biotech (Virkinase) have also either launched or working on their versions streptokinase in India.
Streptokinase is a protein produced by beta-haemolytic streptococcus. It belongs to a group of medications known as fibrinolytics, and works by activating plasminogen through cleavage to produce plasmin.
Streptokinase is used to break up blood clots in the blood vessels of leg veins, lungs and around the heart.
Streptokinase injection can dissolve blood clots that form in the heart, blood vessels, or lungs after a heart attack, or some other disease process.
Shasun has biotech facility at Velacherry, Chennai, southern India The facility is involved in the creation of biotechnology capabilities & capacities especially in the area of protein processing solutions to provide services for the biotech & pharmaceutical companies.
Shasun Chemicals and Drugs Ltd was founded in 1976 and its headquarters are in Chennai, Tamilnadu, India. Shasun acquired UK-based Rhodia Pharma through its wholly owned subsidiary Shasun Pharma Solutions Ltd.
Shasun Chemicals & Drugs Ltd posted revenues of Rs. 127 crore, a growth of 5 per cent compared to Q2 FY08 for the quarter ended September 30, 2008. For Q2 FY09, the company suffered forex losses of Rs. 13.50 crore (against Rs. 10.25 crore gain for Q2 last year) resulting in Net Loss of Rs.10.71 crore as against Net Profit of Rs 6.89 crore for the corresponding quarter of last year.
On a consolidated basis, revenues for the quarter stood at Rs 219 crore compared to Rs 206 crore for Q2FY08, registering a growth of 6%. The Net Loss of the period
stood at Rs. 19.04 crores as against Net Profit of Rs. 8.2 crore for the corresponding quarter of previous year.
Shasun entered into a non-exclusive licensing agreement with Merck & Co., Inc last year on its proprietary cross-coupling copper technology (also known as Buchwald technology) to manufacture and commercialize active pharmaceutical ingredients. The Buchwald cross-coupling technology is one of the most popular technologies in the pharmaceutical area allowing increasingly complex new drugs to be manufactured in an efficient and economical way.
Shasun API facility at Puducherry was established in 1986. The Pondicherry facility is a dedicated plant for the manufacture of Ibuprofen. Shasun is one of the largest manufacturers of ibuprofen in the world. The plant is inspected multiple times by the FDA, MCA and other regulatory bodies in countries across Europe, North America and others. Shasun’s ibuprofen supply chain includes Boots Co, UK – the original innovator of ibuprofen. Shasun offers complete spectrum of ibuprofen derivatives such as S+ Ibuprofen, Ibuprofen Lysinate, and Ibuprofen Sodium.
Shasun Pharma Solutions is the vertically integrated chemistry partner for the pharmaceutical industry. Its services include innovative process research and development, small scale manufacture for clinical trial supply and full scale commercial manufacture of advanced intermediates and API’s.
Shasun Pharma Solutions is carrying out complex multistage organic syntheses, including chemistry in liquid ammonia, organometallic chemistry, halogenations, Friedel-Crafts reactions and reductions, as well as powerful chiral syntheses such as Jacobsen chiral epoxidation and kinetic resolution.